Literature DB >> 27815686

CDK4 in lung, and head and neck cancers in old age: evaluation as a biomarker.

J Banerjee1, R Pradhan1, A Gupta2, R Kumar2, V Sahu2, A D Upadhyay3, P Chaterjee1, S Dwivedi3, S Dey4, A B Dey5.   

Abstract

BACKGROUND: Cyclin dependent kinases (CDK) are key factors in promoting the initiation and development of tumors. These kinases are important for maintenance of mitochondrial biogenesis and imbalance in their expression in old age may lead to the oxidative stress. Lung cancer (LC), and head and neck squamous cell carcinoma (HNSCC) are two very prominent cancers in older Indians. Both the cancers are showing increasing trend in older population. The present study assessed serum concentration of one of the kinases; CDK4 in older LC and HNSCC patients.
METHODS: The study included 100 subjects each of LC and HNSCC; and older subjects without cancer or any major health problems as controls. Serum CDK4 concentration was estimated using real-time label-free Surface plasmon resonance (SPR) and was verified by western blot.
RESULTS: Significant elevation in serum CDK4 was observed in cases with LC and HNSCC compared to controls. HNSCC patients with higher CDK4 expression had distinctly shorter survival than patients with comparatively lower CDK4 expression. No such difference was observed in LC patients. The germ line mutation study of this gene in Exon-2 was performed and none was observed among cases and controls.
CONCLUSION: It can be concluded that older patients with HNSCC and lung cancer have raised serums CDK4 levels, which has the potential to emerge as a biomarker in clinical practice.

Entities:  

Keywords:  Cyclin-dependent kinase 4; Head and neck squamous cell carcinoma; Lung cancer; Surface plasmon resonance

Mesh:

Substances:

Year:  2016        PMID: 27815686     DOI: 10.1007/s12094-016-1565-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  22 in total

1.  Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.

Authors:  A S Lundberg; R A Weinberg
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

2.  Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas.

Authors:  A Perry; K Anderl; T J Borell; D W Kimmel; C H Wang; J R O'Fallon; B G Feuerstein; B W Scheithauer; R B Jenkins
Journal:  Am J Clin Pathol       Date:  1999-12       Impact factor: 2.493

3.  Analysis of 2167 head and neck cancer patients' management, treatment compliance and outcomes from a regional cancer centre, Delhi, India.

Authors:  B K Mohanti; P Nachiappan; R M Pandey; A Sharma; S Bahadur; A Thakar
Journal:  J Laryngol Otol       Date:  2006-09-25       Impact factor: 1.469

Review 4.  Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Authors:  Sagrario Ortega; Marcos Malumbres; Mariano Barbacid
Journal:  Biochim Biophys Acta       Date:  2002-03-14

5.  Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors.

Authors:  Daniel Lindberg; Ola Hessman; Göran Akerström; Gunnar Westin
Journal:  Neuroendocrinology       Date:  2007-07-30       Impact factor: 4.914

6.  Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma.

Authors:  Yoh Dobashi; Akiteru Goto; Masashi Fukayama; Akihisa Abe; Akishi Ooi
Journal:  Int J Cancer       Date:  2004-07-01       Impact factor: 7.396

7.  Enhanced malignant tumorigenesis in Cdk4 transgenic mice.

Authors:  Paula L Miliani de Marval; Everardo Macias; Claudio J Conti; Marcelo L Rodriguez-Puebla
Journal:  Oncogene       Date:  2004-03-11       Impact factor: 9.867

8.  Novel germline CDK4 mutations in patients with head and neck cancer.

Authors:  Maimoona Sabir; Ruqia Mehmood Baig; Ishrat Mahjabeen; Mahmood Akhtar Kayani
Journal:  Hered Cancer Clin Pract       Date:  2012-08-29       Impact factor: 2.857

9.  Protein signature of lung cancer tissues.

Authors:  Michael R Mehan; Deborah Ayers; Derek Thirstrup; Wei Xiong; Rachel M Ostroff; Edward N Brody; Jeffrey J Walker; Larry Gold; Thale C Jarvis; Nebojsa Janjic; Geoffrey S Baird; Sheri K Wilcox
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

10.  Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China.

Authors:  Weiyi Fang; Xin Li; Qingping Jiang; Zhen Liu; Huiling Yang; Shuang Wang; Siming Xie; Qiuzhen Liu; Tengfei Liu; Jing Huang; Weibing Xie; Zuguo Li; Yingdong Zhao; Ena Wang; Francesco M Marincola; Kaitai Yao
Journal:  J Transl Med       Date:  2008-06-20       Impact factor: 5.531

View more
  5 in total

1.  A comprehensive investigation using meta-analysis and bioinformatics on miR-34a-5p expression and its potential role in head and neck squamous cell carcinoma.

Authors:  Jixi Li; Kang Liu; Tingting Zhang; Zhendong Yang; Rensheng Wang; Gang Chen; Min Kang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  miR-33a inhibits cell proliferation and invasion by targeting CAND1 in lung cancer.

Authors:  M Kang; Y Li; Y Zhao; S He; J Shi
Journal:  Clin Transl Oncol       Date:  2017-09-04       Impact factor: 3.405

Review 3.  Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention.

Authors:  Sharmistha Dey; Abhay Kumar Singh; Abhinay Kumar Singh; Kartik Rawat; Joyita Banerjee; Vertica Agnihotri; Deepak Upadhaya
Journal:  Med Oncol       Date:  2022-01-20       Impact factor: 3.064

4.  Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma.

Authors:  Zhong-Liu Wei; Xin Zhou; Chen-Lu Lan; Hua-Sheng Huang; Xi-Wen Liao; Shu-Tian Mo; Yong-Guang Wei; Tao Peng
Journal:  BMC Gastroenterol       Date:  2022-02-22       Impact factor: 3.067

5.  Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCC.

Authors:  Asier Rabasco Meneghetti; Alex Zwanenburg; Annett Linge; Fabian Lohaus; Marianne Grosser; Gustavo B Baretton; Goda Kalinauskaite; Ingeborg Tinhofer; Maja Guberina; Martin Stuschke; Panagiotis Balermpas; Jens von der Grün; Ute Ganswindt; Claus Belka; Jan C Peeken; Stephanie E Combs; Simon Böke; Daniel Zips; Esther G C Troost; Mechthild Krause; Michael Baumann; Steffen Löck
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.